Silk Road Medical, Inc SILK
27.49 0.00 (+0.00%)
At closeSep 16, 2024, 4:00 PM EDT
27.49 Day range 27.50
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 20.75 -24.5% downside
Now 27.49
- Target (low)
- 8.00
- Target (mean)
- 20.75
- Target (high)
- 27.50
Ratings (0m) 1 0 buy · 0 hold · 1 sell
- Strong buy0
- Buy0
- Hold0
- Sell0
- Strong sell1
Recommendation trend
- This month 1
- 1 month ago 9
- 2 months ago 10
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.35 | -0.36 – -0.34 | -0.33 | -6.1% | 49.26M | +10.9% | 2 |
| Next quarter | -0.34 | -0.36 – -0.33 | -0.33 | -3.0% | 51.24M | +8.4% | 2 |
| Current year | -1.46 | -1.49 – -1.44 | -1.44 | -1.4% | 199.98M | +12.9% | 2 |
| Next year | -1.31 | -1.41 – -1.22 | -1.46 | +10.3% | 222.32M | +11.2% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 10, 2023 | Piper Sandler | Maintained | Neutral | Neutral |
| Oct 10, 2023 | CL King | Downgrade | Buy | Neutral |
| Oct 10, 2023 | Citigroup | Downgrade | Buy | Sell |
| Oct 10, 2023 | B. Riley Securities | Downgrade | Buy | Neutral |
| Oct 10, 2023 | Stifel | Downgrade | Buy | Hold |
| Sep 20, 2023 | Argus Research | Downgrade | Buy | Hold |
| Sep 5, 2023 | Oppenheimer | Initiated | — | Outperform |
| Aug 13, 2023 | Citigroup | Maintained | Buy | Buy |
| Aug 1, 2023 | Stifel | Maintained | Buy | Buy |
| Aug 1, 2023 | B. Riley Securities | Maintained | Buy | Buy |
| Jul 11, 2023 | B of A Securities | Downgrade | Buy | Underperform |
| Jul 11, 2023 | JP Morgan | Downgrade | Overweight | Neutral |
| Jul 10, 2023 | Citigroup | Reiterated | Buy | Buy |
| May 22, 2023 | CL King | Initiated | — | Buy |
| May 21, 2023 | Argus Research | Maintained | Buy | Buy |
| May 14, 2023 | Wolfe Research | Downgrade | Peer Perform | Underperform |
| May 9, 2023 | Piper Sandler | Maintained | Neutral | Neutral |
| May 9, 2023 | Citigroup | Maintained | — | Buy |
| Apr 2, 2023 | Citigroup | Upgrade | Neutral | Buy |
| Mar 30, 2023 | B. Riley Securities | Initiated | — | Buy |
| Mar 9, 2023 | Citigroup | Upgrade | Sell | Neutral |
| Feb 6, 2023 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Jan 8, 2023 | Argus Research | Maintained | Buy | Buy |
| Nov 21, 2022 | Argus Research | Maintained | Buy | Buy |
| Jul 17, 2022 | Stifel | Maintained | — | Buy |
| Jul 10, 2022 | Citigroup | Downgrade | Neutral | Sell |
| May 16, 2022 | Citigroup | Maintained | — | Neutral |
| Apr 5, 2022 | Wolfe Research | Initiated | — | Outperform |
| Apr 3, 2022 | Piper Sandler | Maintained | — | Neutral |
| Feb 24, 2022 | Citigroup | Maintained | — | Neutral |